Director/PDMR Shareholding

RNS Number : 7309A

Instem plc

04 February 2022

 

4 February 2022

Instem plc

("Instem" or "the Company")

Exercise of Options, PDMR Dealing, Issue of Equity and Total Voting Rights

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that it was notified on 2 February 2022 that certain Directors of the Company exercised share options ("Share Options") over, in aggregate, 100,000 ordinary shares of 10 pence each in the Company ("Ordinary Shares").

Subsequently, on 2 February 2022, certain Directors sold a portion of the Ordinary Shares issued on the exercise of the Share Options to finance the cost of exercise (where applicable) and associated tax liabilities.

Details of the Directors who participated in the exercise of Share Options and subsequent sale of Ordinary Shares are as follows:

	Number of:		Exercise price per Ordinary Share	Resultant interest in Ordinary Shares	Resultant interest in Ordinary Shares (%)
Name of Director	Share Options exercised	Ordinary Shares sold
Phil Reason	80,000a	40,000	Nil	770,714	3.46%
Nigel Goldsmith	20,000b	12,500	176p	10,000	0.04%

^a   In relation to options granted on 22 February 2018 and exercisable on or before 15 March 2022

^b In relation to options granted on 7 February 2012 and exercisable on or before 7 February 2022

Issue of Equity and Admission

Application will be made to the London Stock Exchange for the admission of the 100,000 new Ordinary Shares to trading on AIM ("New Ordinary Shares"). Admission is expected to take place at 8.00 a.m. on 9 February 2022.  

Total voting rights

Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 22,289,856 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 22,289,856.

The figure of 22,289,856 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Instem plc	via Walbrook
Singer Capital Markets (Nominated Adviser & Broker)	[phone]
Peter Steel Rachel Hayes Alex Bond
Stifel Nicolaus Europe Limited (Joint Broker)	[phone]
Ben Maddison
Alex Price
Walbrook Financial PR	[phone]
Tom Cooper	[e-mail]
Nick Rome

About Instem  

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

To learn more about Instem solutions and its mission, please visit  www.instem.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Phil Reason
2	Reason for the notification
a)	Position/status	Chief Executive Officer and PDMR
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Instem plc
b)	LEI	213800PILYUFNNROQX68
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 10p each
	Identification code	GB00B3TQCK30
b)	Nature of the transaction	1.  Exercise of Options 2.  Sale of Ordinary Shares
c)	Price(s) and volume(s)
			Price	Volume(s)
			1.  Nil (exercise price)	80,000
			2.  745p	40,000
d)	Aggregated information	n/a - the exercise of options over Ordinary Shares and the sale of Ordinary Shares each completed as single transactions
	- Aggregated volume
	- Price
e)	Date of the transaction	2 February 2022
f)	Place of the transaction	In respect of the exercise of options over Ordinary Shares: outside a trading venue In respect of the sale of Ordinary Shares: London Stock Exchange, AIM Market (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Nigel Goldsmith
2	Reason for the notification
a)	Position/status	Chief Financial Officer and PDMR
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Instem plc
b)	LEI	213800PILYUFNNROQX68
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 10p each
	Identification code	GB00B3TQCK30
b)	Nature of the transaction	Exercise of Options
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			1.  176p (exercise price)	20,000
			2.  745p	12,500
d)	Aggregated information	n/a - the exercise of options over Ordinary Shares and the sale of Ordinary Shares each completed as single transactions
	- Aggregated volume
	- Price
e)	Date of the transaction	2 February 2022
f)	Place of the transaction	In respect of the exercise of options over Ordinary Shares: outside a trading venue In respect of the sale of Ordinary Shares: London Stock Exchange, AIM Market (XLON)

 

END

 

 

DSHGIGDDLGGDGDS